Welcome to our dedicated page for Apellis Pharmace SEC filings (Ticker: APLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Apellis Pharmaceuticals, Inc. (APLS) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a commercial-stage biopharmaceutical issuer listed on the Nasdaq Global Select Market, Apellis uses filings such as Forms 10-K, 10-Q, 8-K, and others to report on its business, financial condition, risk factors, and material events related to its complement-based therapies SYFOVRE and EMPAVELI/Aspaveli.
In these filings, investors can review detailed information on revenue from SYFOVRE and EMPAVELI, research and development spending for ophthalmology and rare disease programs, and the status of key clinical trials such as GALE and VALIANT. Risk factor and management discussion sections typically describe the scientific and regulatory considerations associated with targeting C3 in geographic atrophy, C3 glomerulopathy, primary IC-MPGN, and paroxysmal nocturnal hemoglobinuria.
Current reports on Form 8-K, such as the Royalty Buy-Down Agreement with Swedish Orphan Biovitrum AB (Sobi), document material definitive agreements that affect Apellis’ economics, including ex-U.S. royalty structures for Aspaveli and related financing consents. These filings help clarify how collaborations and capital arrangements support the company’s commercialization and pipeline strategy.
On Stock Titan, Apellis filings are updated in near real time as they are posted to EDGAR. AI-powered summaries highlight key points from lengthy documents, helping readers quickly understand topics like royalty arrangements, cash runway, product revenue trends, and major clinical or regulatory milestones. Users can also review Forms 4 and other insider transaction reports to monitor trading activity by Apellis directors and executives, alongside proxy and governance disclosures that describe compensation and board oversight. This page is a central resource for analyzing the regulatory record behind APLS stock.
Apellis Pharmaceuticals (APLS) reported an insider transaction by CFO Timothy Sullivan. On October 21, 2025, he exercised stock options for 10,000 shares at $10.03 and sold 10,000 shares at $28.03 under a Rule 10b5-1 trading plan.
After these transactions, he held 110,936 shares directly and 60,396 shares indirectly through The Timothy E Sullivan Irrevocable Trust of 2023. He also reported 232,903 derivative securities (stock options) beneficially owned following the transactions.
Apellis Pharmaceuticals (APLS) General Counsel David Watson reported a sale of 5,000 shares of common stock at $25.22 on 10/16/2025 pursuant to a Rule 10b5-1 trading plan dated March 3, 2025.
After the transaction, he beneficially owned 113,730 shares directly, plus 10,000 shares held indirectly via a custodial account for his minor children and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023.
Apellis Pharmaceuticals (APLS): Director insider activity reported on Form 4. On 06/24/2025, the reporting person transferred 4,787 shares for no consideration to Epidarex. On 10/10/2025, Epidarex sold 31,092 shares at a weighted average price of $23.7211 under a Rule 10b5-1 trading plan adopted on June 20, 2025. Following the sale, 3,837 shares were held indirectly via Epidarex, then distributed for no consideration, resulting in 0 shares held indirectly. Direct ownership after the 06/24 transfer was 153,606 shares.
Apellis Pharmaceuticals director Dunlop A. Sinclair reported multiple dispositions of Apellis common stock on 09/30/2025. The filing shows a sale of 31,092 shares at a weighted average price of $22.58 (individual sale prices ranged from $22.23 to $22.74). The filer states these sales were executed under a Rule 10b5-1 trading plan adopted by Epidarex Capital I LP on June 20, 2025. The report lists an additional 3,837-share distribution at no consideration and includes a separate disposition line showing 158,393 shares disposed, without price detail in the table. Sinclair is identified as a director and as having indirect ownership through Epidarex, which holds voting and dispositive power over the shares.
Dunlop A. Sinclair, a director of Apellis Pharmaceuticals (APLS), reported multiple dispositions of Apellis common stock on 09/19/2025. Sales include 31,092 shares sold under a Rule 10b5-1 plan at a weighted-average price of $22.95 (execution prices ranged $22.73–$23.27). A separate distribution of 3,837 shares was recorded as a stock distribution for no consideration. The reported holdings after the first two transactions were 68,908 and 65,071 shares, respectively, held indirectly through Epidarex Capital I LP, of which Sinclair is a general partner and may be deemed to have voting and dispositive power. The Form 4 was signed by an attorney-in-fact on behalf of Sinclair.
Apellis Pharmaceuticals (APLS) filing a Form 144 shows a proposed sale of 93,276 shares of common stock for an aggregate market value of $2,140,917.00, to be executed through Stifel Nicolaus & Company on Nasdaq on 09/19/2025. The shares were acquired in three tranches: 62,441 shares on 08/21/2013, 31,478 shares on 12/24/2015, and 6,081 shares on 08/07/2017; all were paid in cash to the issuer. The filer reports no securities sold in the past three months and affirms no undisclosed material adverse information.
David O. Watson, General Counsel of Apellis Pharmaceuticals (APLS), reported a sale of 5,000 shares of Apellis common stock on 09/16/2025 at a price of $24.34 per share under a 10b5-1 trading plan dated March 3, 2025. After the reported transaction, Mr. Watson beneficially owns 118,730 shares directly. The filing also discloses 10,000 shares held in a custodial account for his minor children and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023, over which he disclaims beneficial ownership except to the extent of any pecuniary interest. The Form 4 was signed on 09/18/2025.
Apellis Pharmaceuticals insider James G. Chopas, the company's VP and Chief Accounting Officer, reported a small sale of 189 shares of Apellis common stock on 09/15/2025 at a price of $24.192 per share. The filing states the shares were sold to cover tax withholding related to Restricted Stock Units that vested on 09/12/2025. After the transaction, Mr. Chopas beneficially owned 53,468 shares, held directly. The Form 4 was signed by an attorney-in-fact on 09/16/2025.
Apellis Pharmaceuticals (APLS) Form 144 notice summarizing proposed and recent insider sales. The filing reports a proposed sale of 5,000 common shares through Fidelity Brokerage Services with an aggregate market value of $121,700 and an approximate sale date of 09/16/2025. It shows two prior restricted stock vesting events: 706 shares on 01/21/2024 and 4,294 shares on 01/21/2025, both as compensation. The filing lists three common-share sales by David O. Watson in the past three months totaling $330,600 in gross proceeds. The company has 126,289,910 shares outstanding as stated.
Apellis Pharmaceuticals, Inc. (APLS) Form 144 notice reports a proposed sale of 189 shares of common stock held at Fidelity Brokerage Services with an aggregate market value of $4,572.29. The shares, part of restricted stock that vested on 09/12/2025, were acquired from the issuer as compensation and the filer plans an approximate sale date of 09/15/2025 on NASDAQ. The filing also discloses that the same account sold 548 shares on 09/02/2025 for gross proceeds of $15,386.20. These amounts are small relative to the reported 126,289,910 shares outstanding, and the filer represents no undisclosed material adverse information.
FAQ
What is the current stock price of Apellis Pharmace (APLS)?
What is the market cap of Apellis Pharmace (APLS)?
